Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
BRIDGEWATER, N.J., Nov. 01, 2016 -- Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that John Timberlake, President and Chief Executive Officer and Erick Lucera, Chief Financial Officer are scheduled to present at the Canaccord Medical Technologies & Diagnostic Forum.
| Event: | Canaccord Medical Technologies & Diagnostic Forum |
| Format: | Presentation and One-on-One Meetings |
| Date: | Thursday, November 17, 2016 |
| Time: | 1:30pm ET |
| Location: | New York, NY |
Audio webcasts of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas’ flagship product, V-Go® Disposable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group (646)536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Christopher Hippolyte The Ruth Group (646)536-7023 [email protected]
